HIV Diagnostics Market Is Expected To Reach USD 4.48 Billion By 2022: Radiant Insights, Inc.

“Radiant Insights” includes new market research report on “Global HIV Diagnostics Market Size, Share And Trends Report By 2022: Radiant Insights” to its huge collection of research reports.

Global HIV Diagnostics Market is expected to reach USD 4.48 billion by 2022, growing at an estimated CAGR of 9.5% from 2015 to 2022, according to a new study by Grand View Research, Inc. Key factors accounting for the growth of this market include the growing need in for the development of more sensitive HIV diagnostic point of care tests which can be easily implemented at the location of patient care in resource limited settings.

Technological development of tests which is expected to introduce a number of novel rapid, point-of-care tests throughout the forecast period is a primary factor expected to fuel the growth of the HIV diagnostics market. Furthermore, government programs and campaigns initiated against HIV, global healthcare efforts to reduce disease incidence, and the presence of high unmet demand in the Middle Eastern and Eastern regions of the market are some key factors expected to serve as lucrative future growth opportunities.

Browse Full Research Report With TOC On “Global HIV Diagnostics Market Analysis By Product (Antibody Tests, Viral Identification Assays, CD4 Testing, Viral Load Testing, Early Infant Diagnosis) And Segment Forecasts To 2022” at:

Further key findings from the study suggest:

  • Antibody HIV diagnostic tests accounted for the largest share of the market in 2014. This large share can be accounted for by the high market usage and penetration rates of these tests which include, ELISA, home access dried blood spot, western blot testing IFA and RIPA.  These tests are highly sensitive and accurate and thus are most commonly used for screening and confirmation of HIV-1 & HIV-2. 
  • Viral Load testing and CD4 testing also accounted for a considerable share of the market in 2014. There is a prevalent in the market for the development of these tests which will make them more sensitive, rapid in nature and portable to the point of care to enhance their market usability and accessibility in resource limited HIV affected regions.
  • It is expected that during the forecast period a number of novel point of care HIV diagnostic products will be commercialized which are currently under clinical development and in product pipelines of key market players. This increase in the range of products s expected to fuel the growth of this market over the forecast period.
  • North America was observed to account for the largest share of the market in 2014, which can be attributed to the presence of a strong healthcare R&D scenario in which the presence of government funding and ongoing corporate efforts to enhance product portfolio are anticipated to accelerate the timelines for new product development. Furthermore, the presence of favorable reimbursements policies for HIV and other infectious diseases is also a factor accounting for this region’s large share.
  • Asia Pacific is expected to grow at a relatively faster rate over the forecast period owing to, the presence of high levels of unmet market demand for HIV screening and testing. Moreover, collaborations among market participants from the western regions is another significant expected to boost the growth of Asia Pacific HIV diagnostics market during the forecast period.
  • Key players of the market include Janssen Diagnostics, Daktari Diagnostics, Cepheid, Hologic and Chembio Diagnostic Systmes Inc.

Browse All Reports of This Category at:

Table of Contents:

HIV Diagnostics Product Outlook (Revenue, USD Million, 2012 – 2022)

• Antibody Tests

 HIV-1 Screening Tests


  Home Access Dried Blood Spot

  Rapid Tests (Dot plot, Agglutination Tests)

 HIV-1 Antibody Confirmatory Tests

  Western Blot Test

  ndirect Immunofluorescent Antibody Assay (IFA)

  Line Immunoassay

  RadioImmunoPrecipitation Assay (RIPA)

 HIV-2 & Group O Diagnostic Tests

  Blood Antibody Tests

  Dried Blood Spot (DBS) Test

  Others and (Oral, Urine)

• Viral Identification Assays

 P24 Antigen Test

 Qualitative PCR Tests

 Viral Culture

• CD4 Testing

•  Viral Load Testing

• Early Infant Diagnostics

Related Reports by Radiant Insights:

About Radiant Insights

Radiant Insights is a market research and consulting company offering syndicated research studies, customized reports, and consulting services. Our market research studies are designed to facilitate strategic decision making, on the basis of extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Using a patented and robust research methodology, we publish exhaustive research reports covering a host of industries such as Technology, Chemicals, Materials, and Energy. Radiant Insights has a strong base of analysts, consultants and domain experts, with global experience helping us deliver excellence in all research projects we undertake.


Media Contact
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Phone: (415) 349-0054, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
State: California
Country: United States